Research programme: microRNA-based Alzheimers disease therapeutics - Microlin Bio/Universite Laval
Latest Information Update: 12 Feb 2016
At a glance
- Originator Universite Laval
- Developer Microlin Bio; Universite Laval
- Class MicroRNAs
- Mechanism of Action MicroRNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease